Management of Gout by Ayurvedic Drug

An Etiopathological Study of Vatarakta wsr to Gout and therapeutic effect(Upshayatmak Parikshan) of Anshumati Kwath

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028225

Enrollment

Registered

2020-10-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

Intervention1: Anshumati Kwatha: minimum 40 patients with Sign and Symptoms of Vatarakta will be given 20ml of Anshumati Kwatha twice daily for 30 days Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: patients presenting with classical sign and symptoms of Vatarakta patients of Hyperuricemia with Gouty arthritis

Exclusion criteria

Exclusion criteria: patients associated with metabolic disorder and systemic disease patients of autoimmune joint disorder except RA

Design outcomes

Primary

Measure	Time frame
relief in sign and symptoms of vataraktaTimepoint: 30 days	—

Secondary

Measure	Time frame
improve quality of life of patients suffering from vataraktaTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Avadhesh Kumar

Government PG Ayurveda College and Hosptal

dravadheshsaroj@gmail.com9455262663

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026